Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher’s disease

H Kelsey, C Christopoulos, A A Gray, S J Machin

Abstract

**Aims**—To investigate the abnormality in platelet function in two patients with type I Gaucher’s disease causing a chronic bleeding tendency despite normalisation of the platelet count after spleen removal.

**Methods**—Routine laboratory methods were used to assess baseline coagulation. Platelet aggregometry was used to assess platelet responses to a range of agonists, and abnormalities were further assessed in mixing experiments using washed platelets and patients’ plasma.

**Results**—Platelets from both patients with Gaucher’s disease failed to agglutinate to ristocetin, despite normal platelet surface glycoprotein (GP) Ib and plasma von Willebrand factor activity. The agglutination of normal washed platelets was abolished by incubation in patient plasma. The inhibitory activity did not lie in the IgG fraction of patient plasma, and was found to be loosely associated with the patient platelet surface.

**Conclusions**—The inhibition of ristocetin induced platelet agglutination in patients with Gaucher’s disease causes a prolonged skin bleeding time. This could be due to the accumulated glucocerebroside in the plasma coating the platelet membrane. It is suggested that the term pseudo-pseudo Bernard-Soulier syndrome would be appropriate, as on initial screening, the abnormality has the features of Bernard-Soulier syndrome, but further investigation shows normal plasma von Willebrand activity and platelet surface GP Ib concentrations. The inhibitory activity is not due to a platelet specific antibody as is the case in pseudo-Bernard Soulier syndrome.

(J Clin Pathol 1994;47:162–165)
Acquired pseudo-pseudo Bernard-Soulier syndrome complicating Gaucher’s disease

was replaced, bleeding at which was successfully prevented by prophylactic platelet transfusions. As a result of red cell and platelet transfusion she formed several red cell and HLA antibodies. After the second hip operation an anaphylactic transfusion reaction occurred, despite compatible blood. Subsequently an additional red cell antibody was found. Since recovery, three units of autologous blood have been placed in long term storage.

A 23 year old caucasian woman was found to have Gaucher’s disease as a child. She had epistaxis and severe menorrhagia as a child and in addition to thrombocytopenia a platelet function abnormality was detected but could not be further defined. When she was 15 years old her spleen was removed for hypersplenism. On recovery the bleeding problems persisted, with heavy menorrhagia despite a normal platelet count. She developed extensive bruising at this time of a road traffic accident when, aged 19 years, she sustained a fractured pelvis. She was referred for investigation of a bleeding tendency when surgical correction of the damage sustained was contemplated.

Blood was collected from the two patients on three separate occasions into EDTA for full blood and platelet counts (STK S, Coulter Electronics, Florida, USA) and into 3-13% trisodium citrate in a ratio of 9 parts blood to 1 part trisodium citrate, for coagulation and platelet function studies. Control plasma and platelets were similarly collected from normal male volunteers. Prothrombin time (PT), thrombin time (TT), and activated partial thromboplastin time (APTT) were performed by routine techniques. Factor VIIIc was assayed by a one stage automated method, von Willebrand factor antigen (vWF:Ag) by ELISA, and ristocetin cofactor activity (vWF:RiCoF) by platelet agglutination. Von Willebrand multimers were assessed by sodium dodecyl sulphate gel electrophoresis, as described before and platelet nucleotides (adenosine triphosphate, adenosine diphosphate; total; and releasable) using a luciferase firefly luminescence technique. Platelet glycoproteins (GP) Ib and IIb/IIIa, platelet surface immunoglobulin, and free platelet bindable immunoglobulin were assessed by a fluorescence flow cytometric method.

Bleeding time was assessed with a template method and platelet aggregometry performed in a four channel aggregometer using the following agonists: ristocetin (Lundbeck, Lyton, England) 1-25, 1-0, 0-7, 0-5 mg/ml; ADP (Sigma Chemical Co Ltd, Poole, Dorset) 5-0, 2-5, 1-0, 0-5 mmol/l; collagen (Hormon Chemie, Munich, Germany) 4-0, 1-0 μg/ml; and arachidonate (Sigma) 1-0 μl. Porcine FVIII complex (Porton, Maidenhead, Berkshire) and cryoprecipitate were used in correction studies with ristocetin.

In mixing experiments washed platelets were used (three washes in Tyrodes buffer with 10 mM EDTA and 10 ng/ml prostacyclin analogue (ZK36 374 Schering Chemicals) and then resuspended in 1:4 human albumin with Tyrodes buffer, as described before. Patient and control platelets were then incubated with patient or control plasma and agglutination to ristocetin tested immediately and after 1 hour of incubation at room temperature. Immunoglobulin G fractions of patient and control sera were isolated by affinity chromatography using a protein G column, eluted with glycine HCl buffer (pH 2-8), and then dialysed against phosphate buffered saline (pH 7-2) to give a final concentration of 5-10 mg/ml. IgG fractions were incubated with washed platelets for one hour and cryoprecipitate then added before testing ristocetin induced agglutination.

Results

Both patients had normal platelet counts and initial clotting screens (table). The bleeding time was >15 minutes in both cases. Platelet aggregation responses to adenosine diphosphate, collagen, and arachidonic acid were normal (table). Ristocetin induced agglutination was absent at all concentrations tested. This did not correct with proline F VIII, or cryoprecipitate and ristocetin, and there was no agglutination on the addition of cryoprecipitate alone (representative traces fig 1A).

Factor VIIIc and vWF:Ag and vWF:RiCoF activities were normal (table).

Platelet surface glycoproteins Ib and IIb/IIIa were present in normal amounts on both patients’ platelets. Free platelet bindable immunoglobulin was detected in both patient sera, and platelet surface immunoglobulin was raised in the second patient. This immunoglobulin reacted with Bernard-Soulier platelets in both cases (results not shown).

The response of washed normal platelets to ristocetin was abolished after 1 hour of incubation in patient plasma (fig 1B). This inhibitory activity was not present in the IgG fraction of patient sera (fig 2A). The inhibitory activity was loosely associated with patient platelets as washing of patient platelets restored ristocetin responses when they were tested immediately after resuspending in

![Table](https://via.placeholder.com/150)

Results of initial investigations—full blood count, coagulation screen, platelet function and bleeding time—patient and control values

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Case 1</th>
<th>Case 2</th>
<th>Normal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelets × 10⁹</td>
<td>179</td>
<td>174</td>
<td>150–450</td>
</tr>
<tr>
<td>PT (control)</td>
<td>13s (12)</td>
<td>15s (13)</td>
<td>11–15s</td>
</tr>
<tr>
<td>APTT (control)</td>
<td>39s (36)</td>
<td>39s (43)</td>
<td>30–40s</td>
</tr>
<tr>
<td>TT (control)</td>
<td>10s (13)</td>
<td>16s (13)</td>
<td>11–15s</td>
</tr>
<tr>
<td>FVIII:Ag</td>
<td>0-95</td>
<td>0-66</td>
<td>0-5–2-0</td>
</tr>
<tr>
<td>vWF:Ristocetin</td>
<td>1-35</td>
<td>0-78</td>
<td>0-5–2-0</td>
</tr>
<tr>
<td>vWF:RiCoF</td>
<td>1-75</td>
<td>0-85</td>
<td>0-5–2-0</td>
</tr>
<tr>
<td>vWF:Multimers</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>Platelet nucleotides</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>GP Ib</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>GP IIb/IIIa</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
<tr>
<td>PSIGG</td>
<td>Normal</td>
<td>Normal</td>
<td>Normal</td>
</tr>
</tbody>
</table>

Platelet aggregation:

- Ristocetin 1-25 mg/ml: Absent
- 0-7 mg/ml: Absent
- 0-5 mg/ml: Absent
- ADP: Normal
- Collagen: Normal
- Arachidonate: Primary wave
- Bleeding time: >15 m
plasma and platelets prior incubation for remixing ristocetin on Figure control ristocetin induced patient plasma. Reincubation in patient plasma for 1 hour resulted in loss of the response compared to patient platelets incubated in normal plasma (fig 2B).

Discussion
These two patients with well characterised Gaucher’s disease had a persistent bleeding tendency despite normalisation of the platelet count after spleen removal. In one case this led to severe bleeding during and after surgery, and in the other to persistent menorrhagia resulting in chronic anaemia. Abnormalities in clotting factors in Gaucher’s disease may be caused by impaired synthesis secondary to liver disease. In addition, prolongation of the APTT has been described due to interference by plasma sphingolipid in the phospholipid dependent phases of coagulation, resulting in an apparent deficiency of factor IX\(^4\) and other clotting factors. The in vivo importance of this inhibition was not clear. In our patients clotting screens were repeatedly normal. Both patients had prolonged bleeding times and no platelet agglutination to ristocetin. This was despite normal platelet surface glycoprotein Ib and plasma factor VIII–vWF activities. The inhibitory effect resides in the plasma, as shown by mixing studies, and is loosely associated with the platelet surface because it can be removed by simple washing, so normalising ristocetin agglutination. Myeloma proteins inhibit platelet adhesion and aggregation—particularly adenosine diphosphate induced aggregation,\(^8\) probably by coating the platelet surface. A pseudo-Bernard-Soulier syndrome has been described\(^8\) in which an autoantibody directed against GP Ib, in a patient receiving procarinamide, resulted in loss of function. In our patients, however, the IgG fraction did not inhibit ristocetin induced agglutination, despite the presence of free platelet bindable immunoglobulin in the serum. This latter is not likely to be platelet specific activity, representing HLA antibody, secondary to repeated exposure to blood products. Furthermore, simple washing is unlikely to remove specifically bound IgG, whereas in these experiments inhibitory activity was easily removed by washing.

Macromolecules in the circulation, such as hydroxethyl starch, can induce an acquired von Willebrand type syndrome with low plasma F VIII:vWF Ag concentrations and a bleeding diathesis.\(^10\) Macromolecules, such as HES and dextran, are also adsorbed on to the platelet surface, inducing a thrombocytopenic type effect.\(^11\) A similar effect probably occurs with the accumulated sphingolipid in the plasma of these patients with Gaucher’s disease. An inhibitory effect on the phospholipid phases of coagulation has already been shown, and binding of glycosphingolipid to the platelet surface may interfere with the vWF–ristocetin–GP Ib interaction, giving rise to the platelet function defect described here. We suggest that the term pseudo-pseudo Bernard–Soulier syndrome be applied to the abnormality in platelet function seen in these patients with Gaucher’s disease. Although a plasma factor is responsible for the loss in ristocetin induced agglutination, this is not a platelet specific antibody. The effect is probably caused by excess sphingolipid directly binding to glycoprotein Ib or to the platelet surface adjacent to the GP on the platelet surface. Further studies are required to determine the mechanism exactly. Enzyme replacement treatment in these patients may, by reducing plasma glycosphingolipid concentrations, improve the bleeding tendency.

3 Brady RO, Pentchev PG, Gal AE, et al. Replacement replacement...

H Kelsey, C Christopoulos, A A Gray and S J Machin

doi: 10.1136/jcp.47.2.162

Updated information and services can be found at:
http://jcp.bmj.com/content/47/2/162

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/